Last €111.17 EUR
Change Today -0.52 / -0.47%
Volume 0.0
XP2 On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 4:56 AM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

8510 Colonnade Center Drive

Raleigh, NC 27615

United States

Phone: 919-862-1000

Fax: 919-862-1095

surgery or anesthesia. The FDA approved Solesta through the premarket approval (PMA) process as a Class III Medical Device. The company owns a worldwide license to Solesta with the completion of its acquisition of Oceana Therapeutics, Inc. (Oceana). Solesta also is CE Mark-approved for distribution in Europe and is marketed throughout Europe. Solesta should be protected until May 2014 by a composition and method claims patent, and until July 2015 by a methods of manufacturing patent. Deflux Deflux is a biocompatible tissue bulking agent, consisting of dextranomer microspheres and stabilized sodium hyaluronate. It is indicated for children affected by VUR grades II-IV, a malformation of the urinary bladder that can result in severe infections of the kidneys and irreversible kidney damage. The Deflux PMA application is granted by the FDA. The company owns a worldwide license to Deflux with the completion of its acquisition of Oceana. Deflux should be protected until May 2014 by a composition and method claims patent, and until July 2015 by a methods of manufacturing patent. Fulyzaq (crofelemer) Delayed-Release Tablets Fulyzaq is indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. The company owns rights to crofelemer, the Fulyzaq compound, from Napo Pharmaceuticals, Inc. (Napo). The FDA granted marketing approval for Fulyzaq. Patents for Fulyzaq should provide intellectual property protection to 2018. Fulyzaq should also be eligible for five years of marketing exclusivity from the date of FDA approval, and the product might be entitled to patent term restoration. Giazo (balsalazide disodium) Tablets Giazo is indicated for the treatment of mildly to moderately active UC in male patients 18 years of age and older. The FDA granted marketing approval for this product under the trade name Giazo. The company shipped Giazo to wholesalers and launched Giazo to physicians in 2013. The patent for balsalazide disodium tablets would expire in 2018. Metozolv ODT (metoclopramide hydrochloride) 5 mg and 10 mg Orally Disintegrating Tablets Metozolv ODT is indicated for short-term (4 to 12 weeks) use in adults for treatment of GERD that fails to respond to conventional therapy and for the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis. The patent for Metozolv expires in 2023. Azasan (azathioprine) Tablets Azasan is a FDA-approved drug that suppresses immune system responses and is indicated for preventing rejection of kidney transplants and treatment of severe arthritis. The company owns from aaiPharma LLC (aaiPharma), the right to sell 25, 75 and 100 mg dosage strengths of Azasan in North America. The company offers the 75 and 100 mg dosage strengths of Azasan in the United States. Anusol-HC and Proctocort (hydrocortisone) Creams and Suppositories Anusol-HC (hydrocortisone) 2.5% cream and Proctocort (hydrocortisone) 1% cream are topical corticosteroids indicated for relief of the inflammatory and pruritic, or itching, manifestations of corticosteroid-responsive dermatoses. Anusol-HC (hydrocortisone acetate) 25 mg rectal suppositories and Proctocort (hydrocortisone acetate) 30 mg rectal suppositories are indicated for use in inflamed hemorrhoids and postirradiation proctitis, as well as an adjunct in the treatment of chronic UC and other inflammatory conditions. Pepcid (famotidine) for Oral Suspension Pepcid Oral Suspension is a prescription pharmaceutical product indicated for various gastrointestinal indications, including the treatment of duodenal ulcer, benign gastric ulcer and GERD. The company owns the U.S. prescription pharmaceutical product rights to Pepcid Oral Suspension from Merck & Co., Inc. (Merck). The FDA approved two generic famotidine oral suspension products. The company launched an authorized generic famotidine product to compete with these generic products. Diuril (Chlorothiazide) for Oral Suspension Diuril Oral Suspension is indicated for the treatment of high blood pressure and also as adjunctive therapy in edema associated with congestive heart failure, ci

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XP2:GR €111.17 EUR -0.52

XP2 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $69.81 USD +0.81
Jazz Pharmaceuticals PLC $175.56 USD -0.64
Lupin Ltd 1,489 INR -14.00
Recordati SpA €14.01 EUR -0.08
View Industry Companies
 

Industry Analysis

XP2

Industry Average

Valuation XP2 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.8x
Price/Book 15.2x
Price/Cash Flow 80.9x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SALIX PHARMACEUTICALS LTD, please visit www.salix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.